Actualités

S&P 500 health insurer Centene blew away Q2 earnings forecasts amid lower-than-expected Affordable Care Act Marketplace benefit costs. CNC stock initially moved higher, but shares reversed sharply lower as the company discussed its outlook, including slightly higher Medicaid attrition and a more costly covered population in the second half of 2026. Centene posted Q2 earnings of $2.51 a share, crushing forecasts of $1.09 by $1.42 a share.

The past six months have been a windfall for Oscar Health’s shareholders. The company’s stock price has jumped 86.2%, hitting $27.70 per share. This performance may have investors wondering how to approach the situation.

Oscar Health (OSCR) has been drawing attention after a strong share price run, with investors weighing that performance against mixed valuation signals that suggest the stock is not an obvious bargain. See our latest analysis for Oscar Health. Recent trading has cooled slightly, with the share price down around 3% over the past month and 7 days. That comes after a strong 90 day share price return of about 68% and a very large 3 year total shareholder return, suggesting momentum has been...

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

Oscar Health stock has delivered very strong returns over the past few years, yet the valuation checks present a more mixed picture that stops short of calling it a straightforward bargain. The share price has returned 269.8% over the last 3 years, which puts recent short term pullbacks into the context of a powerful longer term move. Investor expectations around Oscar Health's ability to scale its insurance platform efficiently can support the current valuation, while ongoing execution...

Oscar Health, Inc. (OSCR) reached $29.5 at the closing of the latest trading day, reflecting a -4.13% change compared to its last close.

Goosehead (GSHD) delivered earnings and revenue surprises of +23.08% and +9.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Solid retention, renewals, prudent pricing, exposure growth and improved digitization are expected to help CINF, RGA, OSCR, WTW and AFL outperform Q2 estimates.

Zacks.com users have recently been watching Oscar Health (OSCR) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Oscar Health (OSCR) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.

Oscar Health and other multiline insurers may benefit from diversification, digitalization and M&A trends despite pricing pressure and inflation.

In the closing of the recent trading day, Oscar Health, Inc. (OSCR) stood at $30.61, denoting a -1.48% move from the preceding trading day.

Better pricing, product redesigns and technological advancements are expected to aid Zacks Multiline Insurance industry players like OSCR, RDN, CNO, PLGO and HMN.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

Oscar Health (OSCR) leverages a tech-driven platform and innovative insurance offerings to differentiate in the ACA marketplace. OSCR exhibits strong technical momentum and maintains a 100% “Buy” opinion from Barchart. Shares are up 106% over the past year. OSCR is gaining investor attention, trading near all-time highs, and is expected...

In the most recent trading session, Oscar Health, Inc. (OSCR) closed at $31.2, indicating a +1.27% shift from the previous trading day.

In recent days, Oscar Health has drawn attention for strong revenue growth, expanding exposure to the Affordable Care Act market, and mixed analyst views on its valuation and profitability outlook. At the same time, a family trust linked to director Mario Schlosser sold and converted Class A and Class B shares under a pre-arranged trading plan, highlighting insider portfolio diversification rather than a shift in overall ownership exposure. Now we’ll examine how Oscar’s rapid revenue...

Oscar Health stock has logged a very large 3 year gain, yet recent valuation checks and analyst commentary suggest the shares may still be priced below what some investors expect for its growth profile. With the stock already reflecting strong momentum and mixed views from analysts, the question is whether the current valuation leaves enough room for further upside without stretching fundamentals. Oscar Health has returned about 277.2% over the past 3 years, which puts extra focus on whether...

Here is how Apple Hospitality REIT (APLE) and Oscar Health, Inc. (OSCR) have performed compared to their sector so far this year.

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

The latest trading day saw Oscar Health, Inc. (OSCR) settling at $31.44, representing a -2.3% change from its previous close.

Baird said the outcomes from the final 2025 healthcare exchange risk adjustment transfers support Centene’s prior Q4 commentary and align directionally with Oscar’s comments at a June investor conference.

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.

Oscar Health, Inc. (OSCR) closed at $28.52 in the latest trading session, marking a -3.16% move from the prior day.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how health insurance providers stocks fared in Q1, starting with Oscar Health (NYSE:OSCR).

Oscar Health, Inc. (OSCR) concluded the recent trading session at $29.16, signifying a -2.57% move from its prior day's close.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 5.2% gain for healthcare stocks has fallen short of the S&P 500’s 8.5% rise.

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Investors are still underrating this insurance disrupter.